JP2013525473A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525473A5
JP2013525473A5 JP2013508559A JP2013508559A JP2013525473A5 JP 2013525473 A5 JP2013525473 A5 JP 2013525473A5 JP 2013508559 A JP2013508559 A JP 2013508559A JP 2013508559 A JP2013508559 A JP 2013508559A JP 2013525473 A5 JP2013525473 A5 JP 2013525473A5
Authority
JP
Japan
Prior art keywords
group
ortho
meta
optionally substituted
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013508559A
Other languages
English (en)
Japanese (ja)
Other versions
JP5812541B2 (ja
JP2013525473A (ja
Filing date
Publication date
Priority claimed from HU1000243A external-priority patent/HUP1000243A2/hu
Application filed filed Critical
Publication of JP2013525473A publication Critical patent/JP2013525473A/ja
Publication of JP2013525473A5 publication Critical patent/JP2013525473A5/ja
Application granted granted Critical
Publication of JP5812541B2 publication Critical patent/JP5812541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013508559A 2010-05-06 2011-05-06 8−ヒドロキシキノリン誘導体 Active JP5812541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1000243 2010-05-06
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (3)

Publication Number Publication Date
JP2013525473A JP2013525473A (ja) 2013-06-20
JP2013525473A5 true JP2013525473A5 (enExample) 2014-06-26
JP5812541B2 JP5812541B2 (ja) 2015-11-17

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508559A Active JP5812541B2 (ja) 2010-05-06 2011-05-06 8−ヒドロキシキノリン誘導体

Country Status (21)

Country Link
US (1) US8871937B2 (enExample)
EP (1) EP2566849B1 (enExample)
JP (1) JP5812541B2 (enExample)
KR (1) KR101837974B1 (enExample)
CN (1) CN102985407B (enExample)
AU (1) AU2011256989B2 (enExample)
CA (1) CA2798419C (enExample)
CY (1) CY1122426T1 (enExample)
DK (1) DK2566849T3 (enExample)
EA (1) EA021026B1 (enExample)
ES (1) ES2761832T3 (enExample)
HR (1) HRP20192278T1 (enExample)
HU (2) HUP1000243A2 (enExample)
MX (1) MX337999B (enExample)
NZ (1) NZ603967A (enExample)
PL (1) PL2566849T3 (enExample)
PT (1) PT2566849T (enExample)
RS (1) RS59678B1 (enExample)
SI (1) SI2566849T1 (enExample)
SM (1) SMT201900710T1 (enExample)
WO (1) WO2011148208A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) * 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
WO2017066245A1 (en) * 2015-10-12 2017-04-20 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟(胺)基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015179A1 (en) 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AU2474399A (en) 1998-01-26 1999-08-09 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
DE60040397D1 (de) 1999-08-27 2008-11-13 Cytovia Inc Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
US6521617B2 (en) 2000-10-13 2003-02-18 The Johns Hopkins University Treatment of apoptotic cell death
WO2002048092A2 (en) 2000-12-15 2002-06-20 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
EP1414948B1 (en) 2001-07-10 2009-09-16 Biogen Idec Inc. Inhibition of apoptosis process and improvement of cell performance
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
EA200401070A1 (ru) 2002-02-13 2005-02-24 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы лечения сосудистых заболеваний
WO2005072295A2 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7462724B2 (en) 2005-11-15 2008-12-09 Abbott Laboratories Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP2139460A4 (en) * 2007-03-20 2011-09-07 Univ Brandeis COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
CA2687187A1 (en) 2007-05-25 2008-12-18 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
US10301265B2 (en) * 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
EP2521551A4 (en) * 2010-01-06 2013-08-21 Errico Joseph P METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors

Similar Documents

Publication Publication Date Title
JP2020530487A5 (enExample)
JP2019518766A5 (enExample)
JP2010520264A5 (enExample)
RU2013147400A (ru) Способ получения производных кето-бензофурана
JP2016505614A5 (enExample)
JP2014508811A5 (enExample)
JP2013525473A5 (enExample)
JP2015508092A5 (enExample)
JP2015509535A5 (enExample)
JP2009263394A5 (enExample)
JP2016121196A5 (enExample)
JP2010520265A5 (enExample)
JP2017504635A5 (enExample)
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
JP2017508733A5 (enExample)
JP2017533237A5 (enExample)
JP2013544860A5 (enExample)
JP2016507581A5 (enExample)
JP2011517443A5 (enExample)
JP2017519754A5 (enExample)
JP2009538910A5 (enExample)
IL278579B2 (en) Heteroaryl compounds and uses thereof
JP2013511511A5 (enExample)
JP2016529315A5 (enExample)
SI3102573T1 (en) SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7